X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Panacea Biotech Fact Sheet, Panacea Biotech Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Fact Sheet   (PANB)

Here is the latest financial fact sheet of Panacea Biotech. For more details, see the Panacea Biotech quarterly results and Panacea Biotech share price and chart. For a sector overview, read our pharmaceuticals sector report.

PANACEA BIOTECH Price History

Price Rs 136.2
Mkt Cap Rs m 8,342
Vol '000 20.1
P/E X 73.2
P/CF X -20.1
EPS (TTM) Rs 1.9
% ch % 2.2
No. of shares m 61.25
% ch week % -4.8
% ch 1-mth % -3.7
% ch 12-mth % 7.0
52 week H/L Rs 178.3/103.0
(As on Jun 29, 2017 03:36:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PANACEA BIOTECH Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
PANACEA BIOTECH EQUITY SHARE DATA
High Rs248241195159149 
Low Rs59152686482 
Sales per share (Unadj.) Rs134.7189.8115.999.384.1 
Earnings per share (Unadj.) Rs12.223.6-33.6-38.2-18.3 
Diluted earnings per shareRs13.323.6-33.6-38.2-18.3 
Cash flow per share (Unadj.) Rs19.735.8-21.0-24.2-6.7 
Dividends per share (Unadj.) Rs0.250.75000 
Adj. dividends per shareRs0.270.750.000.000.00 
Dividend yield (eoy) %0.20.4000 
Book value per share (Unadj.) Rs104.8105.9142.9102.283.7 
Adj. book value per shareRs114.4105.9142.9102.283.7 
Shares outstanding (eoy) m66.8461.2561.2561.2561.25 
Bonus/Rights/Conversions  ESOPBB--- 
Price / Sales ratio x1.11.01.11.11.4 
Avg P/E ratio x12.68.3-3.9-2.9-6.3 
P/CF ratio (eoy) x7.85.5-6.3-4.6-17.2 
Price / Book Value ratio x1.51.90.91.11.4 
Dividend payout %2.03.2000 
Avg Mkt Cap Rs m10,26012,0368,0546,7997,074 
No. of employees `0003.23.63.33.32.8 
Total wages/salary Rs m1,2721,6081,6071,4691,449 
Avg. sales/employee Rs Th2,787.93,229.82,151.81,843.91,874.1 
Avg. wages/employee Rs Th393.9446.7487.0445.3527.0 
Avg. net profit/employee Rs Th253.0401.9-623.2-709.9-407.7 
PANACEA BIOTECH INCOME DATA
Net Sales Rs m9,00211,6277,1016,0855,154 
Other income Rs m9361618854100 
Total revenues Rs m9,93811,7887,1896,1395,254 
Gross profit Rs m1,1702,549-863-861-766 
Depreciation Rs m500745771860711 
Interest Rs m3854731,0071,0381,503 
Profit before tax Rs m1,2211,492-2,553-2,704-2,881 
Minority Interest Rs m000011 
Prior Period Items Rs m-2-6-450-6 
Extraordinary Inc (Exp) Rs m017301731,771 
Tax Rs m402212-542-18817 
Profit after tax Rs m8171,447-2,057-2,343-1,121 
Gross profit margin %13.021.9-12.2-14.1-14.9 
Effective tax rate %32.914.221.26.9-0.6 
Net profit margin %9.112.4-29.0-38.5-21.8 
PANACEA BIOTECH BALANCE SHEET DATA
Current assets Rs m7,4958,1375,0154,3383,810 
Current liabilities Rs m2,0215,7615,1655,1008,365 
Net working cap to sales %60.820.4-2.1-12.5-88.4 
Current ratio x3.71.41.00.90.5 
Inventory Days Days186129198161156 
Debtors Days Days4487354267 
Net fixed assets Rs m8,6348,03612,85912,89814,480 
Share capital Rs m6761616161 
"Free" reserves Rs m6,9276,4244,3732,024903 
Net worth Rs m7,0056,4888,7516,2575,127 
Long term debt Rs m3,0854,2375,1256,8995,832 
Total assets Rs m16,85617,33919,49818,39519,433 
Interest coverage x4.24.2-1.5-1.6-0.9 
Debt to equity ratio x0.40.70.61.11.1 
Sales to assets ratio x0.50.70.40.30.3 
Return on assets %7.111.1-5.4-7.12.0 
Return on equity %11.722.3-23.5-37.4-21.9 
Return on capital %15.919.9-11.5-11.33.6 
Exports to sales %71.861.148.414.924.5 
Imports to sales %39.425.234.06.310.2 
Exports (fob) Rs m6,4657,1043,4379051,264 
Imports (cif) Rs m3,5442,9312,411385525 
Fx inflow Rs m6,5117,1463,4731,2071,539 
Fx outflow Rs m3,8923,3953,045954942 
Net fx Rs m2,6193,751428253597 
PANACEA BIOTECH CASH FLOW
From Operations Rs m 622 780 2,281 -240 599 
From Investments Rs m -1,172 120 -1,239 -612 -438 
From Financial Activity Rs m 276 -852 -1,336 1,049 -303 
Net Cashflow Rs m -275 49 -295 197 -141 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 74.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.6%
FIIs 1.3%
ADR/GDR 0.0%
Free float 23.6%
Shareholders 10,259
Pledged promoter(s) holding 35.1%
 

Company Information

REGD OFF Ambala - Chandigarh Highway, Lalru, Punjab - 140 501
E-MAIL companysec@panaceabiotec.com WEB www.panaceabiotec.com
TELEPHONE (011) 4157 8024 FAX (011) 4167 9070
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Skyline Financial, D-153 A, Ist Flr., Okhla Indl. Area, Phase-I, New Delhi-20
AUDITOR S. R. Batliboi & Co.
CHM: Soshil Kumar Jain COMP SEC: Vinod Goel (GM-Legal) YEAR OF INC: 1985 BSE CODE: 531349 FV (Rs): 1 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   STRIDES SHASUN LTD  PIRAMAL ENTERPRISES  ALEMBIC PHARMA  INDOCO REMEDIES  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   STRIDES SHASUN LTD  PIRAMAL ENTERPRISES  ALEMBIC PHARMA  INDOCO REMEDIES  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Early Gains to Finish Flat; Indigo Slips 2.3%(Closing)

Indian share markets trimmed its early gains in the afternoon session to finish just above the dotted line amid mixed global cues.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

The 'Multibagger IPOs' You Should Be Betting On(The 5 Minute Wrapup)

Jun 22, 2017

Multibagger IPOs are few and far between. Here's how to spot them...

After Farm Loans, Will Govts Waive Off Mudra Loans Next?(Vivek Kaul's Diary)

Jun 19, 2017

If borrowers organise themselves and ask the government to waive off their loans, the government will find it very difficult to say no, having already established a precedent.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS